Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : NEOTHERAPEUTICS (NEOT) (NEOTW) -- Ignore unavailable to you. Want to Upgrade?

To: Pierre Borczuk who wrote (463)	6/4/1998 10:02:00 AM
From: john jansen	Read Replies (1) \| Respond to of 705

Just looked at stock 10,000 shares was this a single trade?

To: Pierre Borczuk who wrote (463)	6/4/1998 1:43:00 PM
From: Marty	Read Replies (1) \| Respond to of 705

I can't really tell if Pierre is answering for Mike or if they are the same person, but it really doesn't matter because those who posts such nonsense are interchangeable. None of them know what they are talking about. The exceptions are those who honestly admit they are traders that jump in to sell stocks for no other reason than that have gone up dramatically. They feel that statistically there will be a pull back and that they can profit make a profit on it. That is their trading strategy and it has nothing to do with the fundamentals of the stock or the company. The rest may start with the same strategy but they try to help their short position by posting "facts" and "opinions" that either attempt to denigrate the company, belittle the research, or assert the stock is too high for some stock market technical reason. When you try to find out PRECISELY what their stock market technical opinions are based on, they finally, if they are honest enough, admit that they don't really know and can't distinguish one factor from another or actually quantify anything. The height (depth?) of ignorance though is an assertion like Pierre's that "Whether NEOT has a promising product ... no one really knows" Really? Does the following statements, quoted from NeuroInvestment, mean anything to the skeptics? "NeoTherapeutics' lead molecule AIT-082 (Neotrophin) has achieved significant time advantage over other programs pursuing restorative/regenerative approaches to the treatment of Alzheimer's. AIT-082 triggers the production of of endogenous neurotrophins specific to a given area, for example, NGF, NT-3, and bFGF in the cortex/hippocampus, CNTF and BDNF in the spinal cord. Thus far, the release appears to be homeostasis/repair enhancing, the factors are released within the context of injury/disease. AIT-082 has oral bioavailablity and good blood brain barrier access, side-stepping the access problems that dog any attempt to introduce these neurotrophins directly. The release of endogenous neurotrophins is greatest in areas of the brain associated with memory functions, such as the hippocampus." (These are but a few statements, taken out of a many page review, and there are others that may be even more significant or qualifying. Anyone interested should read the whole report as well as other research reports available from the web-site or the company.) So when Pierre posts that nobody knows whether NEOT has a promising product, is his opinion based on an assessment of these kinds of reviews and the other scientific studies released OR to just to not knowing what he is talking about? The comments about relying on caretaker responses and what tests are needed are even more ridiculous and as ill informed and are not worth addressing.